The Biopharmaceutical Marketplace 2012

Wednesday, September 19, 2012 (7:30 AM - 12:00 PM)

Navigating for Success in a Challenging Era

Topic Description: 

Changes in the healthcare marketplace are having a profound impact on the biopharmaceutical industry.  This program will review many of the most critical changes, including:

    • Current challenges and opportunities in the Biopharmaceutical Marketplace
    • Likely impact of the Affordable Care Act on Biopharma
    • Demonstrating value for a biopharmaceutical product
    • Comparative Effectiveness and PCORI - Update - impact on biopharmaceuticals
    • Planning for success during the lifecycle of a biopharmaceutical product
    • The new era of diagnostic testing – how will that influence coverage of biopharmaceuticals?
    • The dramatic growth of specialty pharmaceuticals – both large and small molecules
    • The marked shift from blockbuster drugs to niche-products and generics;  impact of diagnostics
    • More rigorous review of biopharmaceutical products by payers – FDA/EMA approval is no longer enough!
    • Changes in health insurance benefits – tiers, copays, step-therapy and other tactics to direct prescribing


What You’ll Learn:

    • What is happening in the biopharmaceutical marketplace – the focus on value, comparative effectiveness and PCORI;  regulatory and payer expectations (US and global); value-driven drug formularies, tiers, and copays;   explosion of specialty drugs (oral and infused); the managed care/payer response
    • The Affordable Care Act –  Impact on biopharmaceuticals
    • Opportunities and challenges – How to plan for success throughout your product’s lifecycle


Who Should Attend:

  • Companies developing new biopharmaceuticals
  • Venture Investors
  • Medical Directors and Pharmacy Directors


Speakers and Panel Moderator:

  • Moderator:  Pete Fullerton, PhD, RPh (President, Strategic Pharmacy Innovations)
  • Fritz Bittenbender (Vice President, Alliance Development and State Government Relations – BIO)
  • Michael del-Aguila, PhD (Senior Director, Head Biometrics, Health Outcomes & Payer Support, Genentech)
  • David Flum, MD, MPH (Professor and Associate Chair, Surgery;  Director, Surgical Outcomes Research, UW)
  • Donna Morgan Murray, PhD (President, ZymoGenetics, Inc – a Bristol-Myers Squibb Company)
  • Chad Murphy, PharmD  – Pharmacy Director, Premera Blue Cross)



7:30 am - 12:00 pm
7:30-8:00 am- Registration
8:00-12:00 pm - Program


Washington State Convention Center, Room 204
800 Convention Place
Seattle, WA 98101

Registration Fees:

WBBA Member- $50.00                    
Non-Member- $75.00                    
Academia, 501(c)3 Nonprofit, Student- $30.00

Thank You to Our Premier Sponsor:

Thank You to Our Innovation Sponsors:




© 2012 Washington Biotechnology & Biomedical Association

Powered by